1. Abstract
Background Dysbiosis of the human gut microbiota has been implicated in the development of Alzheimer’s disease (AD). However, the genetic correlation between gut microbiota and AD is not well addressed.
Methods Using the largest genome-wide association study (GWAS) of gut microbiota genera from the MiBioGen consortium, we conducted the “best-fit” model from PRSice-2 to determine the genetic correlation between 119 genera and AD in a discovery sample (case/control: 1,278/1,293); we then replicated our findings in an independent sample (case/control: 799/778) and further performed meta-analyses to confirm the correlation. Finally, we conducted a linear regression to assess the correlation between the PRSs for the significant genera and the APOE genotype.
Results In the discovery sample, 20 gut microbiota genera were initially identified genetically associated with AD. Three genera (Eubacterium fissicatena as a protective factor, Collinsella and Veillonella as a risk factor) were validated in the replication sample. Meta-analysis confirmed nine genera to have a significant correlation with AD, three of which were significantly associated with the APOE rs429358 risk allele in a direction consistent with their protective/risk designation in AD association. Notably, the proinflammatory genus Collinsella, identified as a risk factor for AD, was positively correlated with the APOE rs429358 risk allele in both samples.
Conclusion Host genetic factors influencing the abundance of nine genera are significantly associated with AD, suggesting that these genera may serve as biomarkers and targets for AD treatment and intervention. Our results highlight that proinflammatory gut microbiota might promote AD development through interaction with APOE. Larger datasets and functional studies are required to understand their causal relationships.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study was funded by NIH grant P20GM121325, NIH grant P20GM121325-02S1 and NIH grant P20GM121325_03S2
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
IRB of the University of Nevada Las Vegas gave ethical approval for this work
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors
